Accordingly, Maher et al. first found out that human primary T lymphocytes expressing a fusion receptor directed to a prostate-specific membrane antigen (PSMA) and containing TCRξ and CD28 signaling elements could efficiently lyse PSMA-expressing tumor cells [23]. This evidence concerns the gene FOLH1 and neoplasm.